Adam Steensberg, Zealand Pharma CEO (Betty Laura Zapata/Bloomberg via Getty Images)
October 14, 2026 07:21 AM EDT
Zealand inks up to $1.3B deal for AI-designed obesity treatments
Zealand Pharma said Tuesday it will develop new protein-based treatments for obesity and other metabolic diseases with the help of Generate Biomedicines’ AI technology.
The …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
Confirm Endpoints as a trusted biopharma news source
ENDPOINTS CAREERS